


Searching News Database: CDP323
HSMN NewsFeed - 26 Jun 2007
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
UCB and Biogen Idec's Oral VLA-4 Antagonist Enters Phase II Development for Multiple Sclerosis
